Ambruticin is a cyclopropyl-pyran acid, representing a new class of antibiotics. It has a relatively broad antifungal spectrum in vitro and is highly active against dimorphic as well as filamentous organisms. Of 24 strains of dermatophytic fungi tested, the majority were susceptible to ambruticin at 0.049 ug/ml or less. The minimal inhibitory concentration for the systemic fungi Histoplasma capsulatum and Blastomyces dermatitidis was 0.049 to 0.39 pg/ml. Ambruticin is fungicidal for metabolizing cells of Microsporum fulvum and does not cause cell leakage of 260-nm absorbing material. The antibiotic is effective orally as well as topically in guinea pigs experimentally infected with Trichophyton mentagrophytes. In mice, a single oral dose of 75 mg/kg produced peak serum levels of 45 pig/ml in 1 h with a serum half-life of 3.1 h. Excretion of the antibiotic is principally by the biliary route.
Ambruticin was obtained from the Myxobacteriales, an order of microorganism that has essentially remained untapped as a source of biologically active agents. Ambruticin, produced by Polyangium cellulosum subsp. fulvum, is a cyclopropyl-pyran acid ( Fig. 1 ) and represents a novel class of antibiotics (8) . Preliminary information revealed that this antibiotic is active in vitro against fungi (8) . Studies therefore were undertaken on the in vitro and in vivo properties of ambruticin, and the findings are presented in this report. Where appropriate, ambruticin was compared with its commercially available counterpart antibiotics; griseofulvin for dermatophytes and amphotericin B for systemic fungi. Some of these data served as the basis for other studies showing ambruticin to be orally active against experimental coccidioidomycosis in mice (7) .
MATERIALS AND METHODS
Antfungal agents. Except as described below, ambruticin was used as the water-soluble sodium salt (W7783A) which was prepared as convenient aqueous stock solutions, e.g., 5 mg/ml, and stored for up to 2 weeks at 4°C or indefinitely at -200C. The waterinsoluble acid of ambruticin (W7783) was used in the guinea pig chemotherapy studies. For oral use, the acid was solubilized in 95% ethanol, placed on sugar cubes, dried, and given to the animals. For In vitro susceptibility determination. Minimal inhibitory concentrations (MIC) were determined in pH 5.6 Sabouraud dextrose broth for all fungi with the exception of the yeast-phase dimorphic organisms which were tested in pH 7.4 brain heart infusion broth. For preparation of inocula, filamentous fungi and yeasts were grown on peptone-yeast extract-dextrose agar, Histoplasma capsulatum, Blastomyces dermatitidis, and Paracoccidioides brasiliensis were converted to the yeast phase at 370C on brain heart infusion agar supplemented with 10% sheep blood. Fungal suspensions of spores, macerated mycelia from poorly sporulating strains, and yeasts were adjusted to provide a final inoculum of 103 to 10" colony-forming units (CFU)/ml. The 
RESULTS
In vitro anfungal spectrum. Twenty-four dermatophytes were tested, and the majority were susceptible to ambruticin at 0.049 ,ug/ml or less (Table 1) . Overall, ambruticin was more active than griseofulvin in the broth dilution test system.
The spectrum against clinical isolates of percutaneous and systemic fungi is presented in Table 2 . Ambruticin is highly active against the yeast and filamentous phases of H. capsulatum and B. dermatitidis; the MIC range was 0.049 to 0.39 ug/ml, and the order of activity appeared similar to amphotericin B. With the -exception of Aspergillus fumigatus, opportunistic fungi Mechanism of action. Unlike amphotericin B, ambruticin did not affect the cell permeability of M. fulvum and there was no increase in 260-nm absorbing material over a 120-min period at 320C (Fig. 2) .
The antibiotic was fungicidal at 370C but not at 40C; after exposing 4 x 104 to 5 x 104 CFU of aleuriospores of M. fulvum per ml to 10 ,ug of ambruticin per ml in pH 7.2 Sabouraud dextrose broth, >99% kill occurred within 24 h at 370C
whereas there was no decrease in viable counts over a 48-h period at 40C or in the control tubes.
Ambruticin appears to be slowly fungicidal; when spores of M. fulvum were exposed to 0.39 ,ug/ml at 370C, there was approximately an 80% reduction in viability within 24 h, and no viable cells were detected at 48 h from an initial challenge of >2 x 104 viable spores per ml (Table 4) .
At 0.098 ,tg/ml, ambruticin continued to exert slow fungicidal action over a 96-h period (>99% kill), and this concentration was analogous to the MIC level for this test organism. Levels below 0.098 ,Ag/ml were neither fungicidal nor totally inhibitory for M. fulvum. When exposed to ambruticin levels greater than 0.39 ,ug/ml for 24 h and examined microscopically, the macroaleuriospores appeared distorted and no germ tubes were evident. At 0.39 and 0.098 Ag of ambruticin per ml, germ tube formation was highly restricted, whereas the spores from the control tubes showed extensive germination accompanied by hyphal formation. Spores of M. fulvum appeared to have a different order of susceptibility than vegetative hyphae (Fig. 3) ; the slope function for spores was 22.89 and that for hyphae was 11.62 (P < 0.02).
Ambruticin at 0.2 ug/ml severely depressed the incorporation of ['4C]uridine into the ribonucleic acid fraction as well as the incorporation rate of [14C]leucine into the trichloroacetic acidinsoluble protein fraction of M. fulvum (Fig. 4) 3 postinfection, ambruticin was adninistered orally at 40 mg/kg twice daily for a total of 10 days. On postinfection day 15 (3 days off drug), the guinea pig mean lesion score was approximately 1.3; by postinfection day 27 (15 days off drug), all the lesions were essentially healed (Fig. 6) . Similar results were obtained with griseofulvin administered at 20 mg/kg twice daily for 10 days. By comparison, infected control animals on day 15 had pronounced lesions, and even on day 27 the mean lesion score was still approximately 3.0. Cultures remained positive for both drug-treated groups as well as for the controls throughout the 45-day culturing period.
The oral efficacy was also tested against a human isolate of T. mentagrophytes that produces a self-limiting infection in guinea pigs. By using the same regimen and parameters, animals in the ambruticin group required treatment for 6 days before the lesions started to heal, whereas, in the griseofulvin group, there was marked improvement after 2 days of treatment. By postinfection day 15 (3 days off drug), the mean lesion score was 0.9 for both drug treatment groups compared to 1.7 for the infected control animals. The lesions were completely healed by day 20 to 22 in both drug treatment groups and by day 30 in the infected controls. Two days after the end of treatment, the number of negative cultures in the ambruticin-treated animals was greater than in the griseofulvintreated group or in the control group-80% versus 20 and 0%, respectively. In the ambruticintreated group, the lesions started to heal at the time the cultures were becoming negative, indicative of a direct antifungal effect. Oral administration of ambruticin was well tolerated by the animals during or after the 10-day treatment period. For griseofulvin the rapid decrease in lesion score, in the presence of positive cultures, probably reflected the reported anti-inflammatory properties of this antibiotic (3). In the topical trial, a 1% solution of ambruticin in polyethylene glycol 400 was as effective as 1% tolnaftate solution in treatment of experimental dermatophytosis in the guinea pig (Fig. 7) . Infection was with the rat isolate of T. (8) .
Although the mode of action for ambruticin remains to be defined, some of its features have been determined. Ambruticin does not affect the cell permeability of M. fulvum as does amphotericin B; miconazole is reported to cause cell leakage in C. albicans (11) . Ambruticin is fungicidal for metabolizing cells of M. fulvum and, in another study, this antibiotic was also fungicidal for C. immitis (7a) . Amphotericin B has been shown to be fungistatic for C. immitis (10) , and griseofulvin is recognized as a static agent (9) The oral 50% lethal dose for ambruticin in mice is >1,000 mg/kg (8) . In the present investigation, no untoward behavioral differences were detected in guinea pigs orally dosed with 80 mg of ambruticin per kg daily for 10 days and observed for an additional 45 days. In separate studies, ambruticin produced no significant drug-related toxic effects in mice orally dosed with 50 mg/kg three times daily for a total of 30 days, and in a single conscious dog, with cumulative doses up to 10 mg/kg intravenously, no changes were detected in blood pressure, heart rate, electrocardiogram, respiration, and tilt response (unpublished data).
Although there is an increasing awareness of systemic fungal infections as public health problems (1, 16) , there is still a paucity of safe and effective agents for the treatment of such diseases as coccidioidomycosis and histoplasmosis. Amphotericin B is the standard drug but, due to its toxicity (14) , it is usually reserved for lifethreatening situations and must be given by slow intravenous infusion for periods up to 16 weeks or longer (2) . There is interest in the newer imidazoles as possible chemotherapeutic agents for the systemic mycoses and, of these, miconazole is in clinical investigation (12, 13) . Although miconazole is much less toxic than amphotericin B, it too must be administered by intravenous infusion for up to 4.25 months (12, 13) . Moreover, these imidazoles do not produce biological cure of experimental coccidioidomycosis in mice (6) 
